Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPension (IS)Profit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Harvard Bioscience (HBIO) EBITDA (2016 - 2025)

Harvard Bioscience (HBIO) has disclosed EBITDA for 16 consecutive years, with $197000.0 as the latest value for Q3 2025.

  • On a quarterly basis, EBITDA rose 110.51% to $197000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was -$46.5 million, a 455.7% decrease, with the full-year FY2024 number at -$2.4 million, down 356.24% from a year prior.
  • EBITDA was $197000.0 for Q3 2025 at Harvard Bioscience, up from -$819000.0 in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $4.5 million in Q4 2022 to a low of -$49.7 million in Q1 2025.
  • A 5-year average of -$2.9 million and a median of -$396000.0 in 2021 define the central range for EBITDA.
  • Biggest YoY gain for EBITDA was 6793.1% in 2022; the steepest drop was 2708.37% in 2022.
  • Harvard Bioscience's EBITDA stood at -$396000.0 in 2021, then surged by 1248.74% to $4.5 million in 2022, then tumbled by 147.24% to -$2.1 million in 2023, then skyrocketed by 275.52% to $3.8 million in 2024, then crashed by 94.78% to $197000.0 in 2025.
  • Per Business Quant, the three most recent readings for HBIO's EBITDA are $197000.0 (Q3 2025), -$819000.0 (Q2 2025), and -$49.7 million (Q1 2025).